Skip to main content
©Matthias Tunger Photodesign

New Research Unit Signaling & Translation (SAT) established

Molecular Targets and Therapeutics,

On January 1, 2023, the new independent research unit “Signaling & Translation” (SAT) was established at Helmholtz Munich under the leadership of Daniel Krappmann. As part of the “Molecular Targets and Therapeutics Center” (MTTC), SAT investigates cellular signaling pathways with the goal of translating novel discoveries into effective new therapies.

The research goal of SAT is to investigate molecular mechanisms of cellular signaling in response to environmental stimuli and immune stimulators. The goal is to understand the physiological significance of pathways and uncover dysfunctions in these processes in the development of disease.

With these findings, SAT is developing new therapeutic methods to enable targeted and improved therapies for human diseases. Key areas for clinical translation are the development of new concepts for the treatment of cancer and immune diseases.

The work of SAT is being supported by four research groups: Signaling & Immunity“ (Prof. Dr. Daniel Krappmann), „Cell Signaling & Chemical Biology“ (Dr. Kamyar Hadian), „Viral Signaling & Targeting Strategies“ (Prof. Dr. Arnd Kieser) and „Genetics & Cellular Engineering“ (Dr. Joel Schick). To support the “Drug Discovery Research” initiative at Helmholtz Munich, SAT provides the “Compound Screening” platform led by Dr. Kamyar Hadian. The platform provides knowledge in a variety of biochemical or cell-based phenotypic samples.

About the scientist:

Prof. Dr. Daniel Krappmann, Head of the Research Unit „Signaling and Translation“ and Group Leader of the research group „Signaling & Immunity“ at Helmholtz Munich.

More information about the Research Unit SAT: